Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2024 annual meeting of shareholders (the “Annual Meeting”) held on May 29, 2024. The detailed results of the vote for the election of directors are set out below:

Name

For

Against

Broker Non-Votes

Nathalie Bernier

344,550,519

28,790

3,089,749

Gary Hu

344,514,922

64,387

3,089,749

Brett Icahn

344,321,103

258,206

3,089,749

Sarah B. Kavanagh

343,504,035

1,075,274

3,089,749

Karen L. Ling

344,545,858

33,451

3,089,749

John A. Paulson

344,406,744

172,565

3,089,749

Russel C. Robertson

344,472,819

106,490

3,089,749

Thomas W. Ross, Sr.

344,356,329

222,980

3,089,749

Brenton L. Saunders

344,497,635

81,674

3,089,749

Andrew C. von Eschenbach, M.D.

344,353,602

225,707

3,089,749

At the Annual Meeting, shareholders also approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers, approved an amendment and restatement of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the “Plan”) to increase the number of common shares authorized for issuance thereunder, and appointed PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm until the close of the Company's 2025 annual meeting of shareholders.

For the purposes of Toronto Stock Exchange (“TSX”) approval with respect to the Plan, the Company relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible inter-listed issuers on a recognized exchange, such as the NYSE.

The final vote tabulation on all matters voted on at the Annual Meeting will be filed with the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile and on the Company’s website at www.bausch.com.

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Media Contact: Chris Clark chris.clark@bausch.com (848) 360-1100

Investor Contact: George Gadkowski george.gadkowski@bausch.com (877) 354-3705 (toll free) (908) 927-0735

Grafico Azioni Bausch plus Lomb (NYSE:BLCO)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Bausch plus Lomb
Grafico Azioni Bausch plus Lomb (NYSE:BLCO)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Bausch plus Lomb